Sarilumab in Polyarticular-Course Juvenile Idiopathic Arthritis: Dose-Finding and 1-Year Analysis of a Phase 2b, Open-Label, Multicenter Study.

Arthritis Care Res (Hoboken) · 2026 · PMC13206441 · PMID 41235938

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an evident trendno p-value reported

An evident trend toward increased rates of neutropenia in younger, lower‐weight patients with pcJIA treated with tocilizumab was observed. 36 , 37 No definitive mechanism is available to explain why younger patients are more prone to neutropenia; however, in general, a greater prevalence of neutropenia has been reported in children. 38 All grade 3/4 neutropenia resolved within a few days.

also in 268 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.